HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
CLDX
Celldex Therapeutics Inc
Healthcare Biotechnology · New Jersey, USA · Reports in usd
Market Cap: $2.21B
Market Cap
$2.21B
Enterprise Val
$1.69B
P/E Ratio
-8.53
P/B Ratio
4.19
Trailing PEG (1Y)
-0.12
As Of
Apr 27, 2026

Overview & Key Metrics

Reporting period: Dec 31, 2025 · Q4 2025
Book Value$527.2M
Gross Margin100.00%
Profit Margin100.00%
Return on Equity-41.67%
Return on Assets-38.86%
Current Ratio10.49
Debt/Equity0.00
LT Debt/Equity0.00
Revenue Per Share0.00

Income Statement

Dec 31, 2025
Revenue$121.0K
Cost of Revenue$0.00
Gross Profit$121.0K
R&D$75.3M
SG&A$11.9M
Operating Expenses$87.3M
Operating Income-$87.2M
Interest Expense$0.00
Tax Expense$0.00
Net Income-$81.3M
EPS (Basic)$-1.23
EPS (Diluted)$-1.23
EBIT-$81.3M
EBITDA-$80.5M
Consolidated Income-$81.3M
Non-Controlling Interests$0.00

Balance Sheet

Dec 31, 2025
Cash & Equivalents$28.9M
Accounts Receivable$2.0M
Inventory$0.00
Current Assets$534.7M
LT Investments$0.00
Property, Plant & Equipment$7.8M
Intangibles$27.2M
Non-Current Assets$48.3M
Total Assets$583.0M
Accounts Payable$1.2M
Current Debt$1.6M
Current Liabilities$51.0M
LT Debt$784.0K
Non-Current Liabilities$4.8M
Total Liabilities$55.8M
Total Debt$2.3M
Retained Earnings-$1.81B
Shareholder Equity$527.2M
Shares Outstanding66,449,471

Cash Flow Statement

Dec 31, 2025
Operating Cash Flow-$63.9M
Investing Cash Flow$55.4M
Financing Cash Flow$1.3M
CapEx-$1.3M
Free Cash Flow-$65.2M
Depreciation & Amort.$816.0K
Stock-Based Comp$8.9M
Acquisitions / Disposals$0.00
Investment Activity$56.7M
Debt Issued/Repaid$0.00
Equity Issued/Repaid$1.3M
Dividends Paid$0.00
Net Change in Cash-$7.2M
Data cached · Meta live · Daily live · Statements live · TTL 24h